Positron emission tomography with 2-[F-18]fluoro-2-deoxy-D-glucose in oncology Part II. The clinical value in detecting and staging primary tumours


Ak I., Stokkel M., Pauwels E.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.126, no.10, pp.560-574, 2000 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 126 Issue: 10
  • Publication Date: 2000
  • Doi Number: 10.1007/pl00008466
  • Title of Journal : JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Page Numbers: pp.560-574

Abstract

The tumoral uptake of 2-[F-18]fluoro-2-deoxy-D-glucose ((18)FdGlc) is based upon enhanced glycolysis. Positron-emission tomography (PET) using (18)FdGlc provides the physiological and metabolic information. (18)FdGlc PET has been used successfully for assessing primary rumours and metastases, prognosis, and planning and for monitoring tumour therapy as well as for early detection of recurrent tumour growth. This review summarises the uptake mechanism of (18)FdGlc in benign and malignant lesions, its relation to histolopathology, and its clinical value for detecting and staging primary tumours.